Restenosis after renal artery angioplasty and stenting: Incidence and risk factors  by Corriere, Matthew A. et al.
From the Southern Association for Vascular Surgery
Restenosis after renal artery angioplasty and
stenting: Incidence and risk factors
Matthew A. Corriere, MD, MS,a Matthew S. Edwards, MD, MS,a
Jeffrey D. Pearce, MD,a Jeanette S. Andrews, MS,b Randolph L. Geary, MD,a and
Kimberley J. Hansen, MD,a Winston-Salem, NC
Background:Management of renal artery stenosis (RAS) with primary renal artery percutaneous angioplasty and stenting
(RA-PTAS) is associated with a low risk of periprocedural death and major complications; however, restenosis develops
in a subset of patients and repeat intervention may be required. We examined the incidence of restenosis after RA-PTAS
and associations with clinical factors.
Methods:Consecutive patients undergoing RA-PTAS for hemodynamically significant atherosclerotic RAS associated with
hypertension or ischemic nephropathy, or both, between October 2003 and September 2007 were identified from a
registry. Restenosis was defined using duplex ultrasound (DUS) imaging as a renal artery postintervention peak systolic
velocity (PSV) >180 cm/s. The incidence and temporal distribution of restenosis was analyzed using survival analysis
based on treated kidneys. Associations between clinical factors and recurrent stenosis were examined using proportional
hazards regression.
Results: RA-PTAS was performed on 112 kidneys for atherosclerotic RAS during the study period. Initial postinterven-
tion renal artery DUS imaging confirming PSV <180 cm/s in 101 kidneys, which formed the basis of this analysis.
Estimated restenosis-free survival was 50% at 12 months and 40% at 18 months. Decreased risk of restenosis was
associated with preoperative statin use (hazard ratio [HR], 0.35; 95% confidence interval [CI], 0.16-0.74; P .006) and
increased preoperative diastolic blood pressure (DBP; HR, 0.70 per 10-mm Hg increase in preoperative DBP; 95% CI,
0.49-0.99; P  .049). No other factors assessed were associated with restenosis.
Conclusion: Restenosis occurs in a substantial number of patients treated with RA-PTAS. Preoperative statin medication
use and increased preoperative DBP are associated with reduced risk of restenosis. In the absence of contraindications,
statins should be considered standard therapy for patients with atherosclerotic renal artery stenosis. ( J Vasc Surg 2009;
50:813-9.)Atherosclerotic renal artery stenosis (RAS) may cause
severe hypertension or renal dysfunction, or both, and is
associated with an increased risk for cardiovascular events.1
Patients with atherosclerotic RAS who have poorly con-
trolled hypertension or progressive deterioration of renal
function, or both, despite appropriate medical manage-
ment, often are treated with renal artery revascularization,
although the benefits associated with treatment remain con-
troversial. Renal artery percutaneous angioplasty and stenting
(RA-PTAS) has become the most common method of renal
artery intervention. Unfortunately, restenosis has been re-
ported in 17% to 44% of arteries after RA-PTAS2-8 and may
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Analyses to date have identified associations between
restenosis after RA-PTAS and renal artery diameter,5,9
stent diameter,10 weight/body mass index,11 and smok-
ing.12 The purpose of this study was to determine the
frequency and predictors of restenosis after primary RA-
PTAS in a single-center cohort of adult patients with ath-
erosclerotic RAS.
METHODS
Study population. This investigation was conducted
with the approval of the Wake Forest University Health
Sciences Institutional Review Board. Consecutive primary
RA-PTAS procedures performed for hemodynamically sig-
nificant atherosclerotic RAS were identified from a proce-
dure registry. All treated patients had hypertension with or
without renal dysfunction, and indications for RA-PTAS
were determined by individual operators. The analysis ex-
cluded RA-PTAS performed for restenosis or fibromuscular
dysplasia.
All procedures were performed by vascular surgeons at
the Wake Forest University School of Medicine between
October 2003 and September 2007. Standard prepara-
tion, procedural management, and follow-up for patients
treated with RA-PTAS at our center have been described
previously.13,14 Balloon-mounted stents were used in all
patients and sized to match the diameter of the distal,
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the time of treatment. Renal duplex ultrasound (DUS)
imaging was performed before the intervention and 24
hours after RA-PTAS. Thereafter, routine DUS surveil-
lance of the renal artery was conducted at 1 and 6 months,
and then at 6-month intervals.
Data collection and management. Clinical data, in-
cluding patient demographics, comorbidities, and laboratory
results, were retrospectively collected from the electronic
medical record. Presence of left ventricular hypertrophy was
determined by baseline electrocardiography. RenalDUSdata,
including peak systolic velocity (PSV), resistive index, acceler-
ation time, and kidney length, were collected from a pro-
spectively maintained clinical vascular laboratory database.
Anatomic information was retrospectively collected
from angiograms performed during RA-PTAS by manual
electronic caliper measurement of archived images. All
measurements were performed in a nonblinded fashion by a
single individual. Angiographic percentage of RAS was
determined by measuring the smallest luminal diameter at
the point of maximal stenosis and comparing it with the
lumen of the main renal artery distal to the lesion and any
poststenotic dilatation, if present. Anatomic locations of
stenotic lesions were classified as described by Baumgartner
et al.3
Estimated glomerular filtration rate (eGFR) was calcu-
lated from the serum creatinine level using the abbreviated
Modification of Diet in Renal Disease formula.15 Renal
dysfunction was categorized as severe for patients with an
eGFR 30 mL/min/1.73 m2, moderate for patients with
eGFR of 30 to 60mL/min/1.73m2, and none for patients
with an eGFR 60 mL/min/1.73 m2. Renal artery resis-
tive index was calculated from segmental velocities as [1–
(end diastolic velocity/peak systolic velocity)].16
Assessment of restenosis. Hemodynamically signifi-
cant recurrent RAS was identified using DUS imaging.
Patients underwent routine DUS examinations immedi-
ately after treatment and then at 1, 3, and 6 months. DUS
studies were performed using a 5.2-MHz curvilinear probe
with Doppler color flow, with either a Philips IU22 (Philips
Healthcare, Andover, Mass) or an ATL HDI 5000 (Ad-
vanced Technology Laboratories, Bothell, Wash) US sys-
tem using a previously described technique.17
Restenosis was defined as renal artery PSV180 cm/s
in a stented artery previously documented as free of reste-
nosis. This DUS criterion for renal artery restenosis has
been used by others18-20 and was internally validated at our
center (Fig 1, online only). Renal artery PSV 180 at the
time of the first postintervention DUS study was consid-
ered residual stenosis and not interpreted as restenosis.
Repeat renal artery angiography or intervention, or both,
was undertaken at the discretion of individual operators in
the setting of hemodynamically significant restenosis on
follow-up DUS imaging accompanied by deterioration of
renal function after initial postintervention improvement or
worsening of hypertension (eg, increased number of anti-
hypertensive agents, increase in blood pressure, or hyper-tensive emergency) after an initial hypertension response to
RA-PTAS.
Statistical analysis. Data on baseline patient comor-
bid medical conditions, blood pressure, medication use,
renal function data, and demographics are reported using
mean  standard deviation for continuous variables and
count (%) for categoric variables. Restenosis was assessed
for the kidneys using models controlling for within-
subject correlation, and data are reported using model-
based mean  standard error. The incidence and temporal
distribution of recurrent RAS were analyzed using survival
analysis based on treated kidneys. Associations between
clinical factors and time to restenosis were examined using
Cox proportional hazards regression. Both of these meth-
ods accounted for correlated observations. Cox propor-
tional hazards regression modeling was performed using
stepwise selection (P  .10 for model entry). Candidate
covariates for model selection are listed in Table I. Results
were evaluated for significance using   0.05, and hazard
ratios (HR) are expressed with 95% confidence intervals
(CI). Statistical analyses were performed using SAS 9.1
software (SAS Institute, Cary, NC).
RESULTS
Incidence of restenosis and associations with clini-
cal factors. Primary RA-PTAS for atherosclerotic RAS was
attempted in 112 kidneys during the study period. Of
these, eight were excluded due to residual stenosis on initial
postintervention renal artery DUS imaging, two were ex-
cluded due to lack of renal artery DUS follow-up data, and
Table I. Candidate covariates for Cox proportional
hazards modeling
Preoperative factors
Age
Race
Gender
Systolic blood pressure (mm Hg)
Diastolic blood pressure (mm Hg)
Estimated glomerular filtration rate
Number of antihypertensive medications
Current smoker
Medication use
Aspirin
Clopidogrel
Statin
Personal history of diabetes
Ipsilateral renal artery peak systolic velocity (cm/s)
Resistive index
Procedural factors
Renal artery diameter
Stent diameter
Stent/artery diameter ratio
Distal protection (complete distal renal artery balloon
occlusion)
Predilation before stent deployment
Unilateral vs staged bilateral RA-PTAS
Incomplete revascularization (ie, unilateral RA-PTAS in the
setting of bilateral RAS)
RA-PTS, Renal artery renal artery percutaneous angioplasty and stenting.one was excluded as a technical failure related to inability to
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91 patients form the basis of this analysis.
Mean preintervention angiographic RAS was 79.1% 
12.9%. Of these stenotic lesions, 73% were categorized as
ostial, 18% involved the proximal renal artery, and 9%
involved the truncal renal artery. Distal renal artery balloon
occlusion was used for embolic protection during 90% of
procedures. Patient baseline demographics are reported in
Table II. Mean patient age was 68.8  10.1 years, all
patients had hypertension, 53%were women, and 87%were
white. According to the eGFR, moderate or severe renal
Table II. Demographics of the 91 study patients
Variable
No. (%) or
mean  SD
Age, y 68.8  10.1
White race 79 (86.8)
Female 48 (52.8)
Weight, kg 75.9  15.9
Smoking
Never 22 (24.4)
Former 45 (50.0)
Current 23 (25.6)
Diabetes 29 (31.9)
Stroke 24 (26.4)
Coronary artery disease 39 (42.9)
COPD 14 (15.4)
History of hypertensive emergency 13 (14.3)
Left ventricular hypertrophy (ECG) 34 (37.4)
Serum creatinine, mg/dL 1.5  0.6
eGFR,a mL/min/1.73m2 50.9  23.1
Renal insufficiency, eGFR
None, eGFR 60 25 (27.5)
Moderate, eGFR 30-60 53 (58.2)
Severe, eGFR 30 13 (14.3)
Ischemic nephropathy (Cr  1.8 mg/dL) 29 (31.9)
Resistive indexb 0.75  0.08
Pre-op blood pressure
Systolic, mm Hg 161.7  26.2
Diastolic, mm Hg 79.1  13.1
Antihypertensive agents 3.3  1.3
Pre-op renal artery PSV, cm/s 269.8  101.0
Significant contralateral RASc 29 (39.7)
Resistive index  0.8 21 (24.4)
Pre-intervention medications
ACE inhibitor or ARB 57 (62.6)
-blocker 63 (69.2)
Calcium channel blocker 55 (60.4)
Diuretic 52 (57.1)
Aspirin 61 (67.0)
Clopidogrel 22 (24.2)
Statin 54 (59.3)
Fibrate 4 (4.4)
ACE, Angiotensin-converting enzyme; ARB, angiotensin receptor blocker;
COPD, chronic obstructive pulmonary disease; ECG, electrocardiogram; PSV,
peak systolic velocity; RAS, renal artery stenosis; SD, standard deviation.
aEstimated glomerular filtration rate using abbreviated modification of diet
in renal disease formula.
bResistive index from the side with the higher B segment renal artery peak
systolic velocity.
cSignificant contralateral RAS defined as PSV / 180 cm/s on preinter-
vention duplex ultrasound imaging.insufficiency was observed in 72% of patients. The meanpreintervention renal artery diameter was 5.6  0.1 mm,
and mean stent diameter was 5.7  0.1 mm.
There were no periprocedural deaths. Estimated restenosis-
free survival adjusted for within-subject correlation was 50%
at 12 months and 40% at 18 months (Fig 2). Proportional
hazards regression analysis demonstrated decreased risk for
restenosis associated with preoperative statin use (HR,
0.35; 95% CI, 0.16-0.74; P  .006) and preoperative
diastolic blood pressure (DBP; HR, 0.70 per 10-mm Hg
increase in preoperative DBP; 95% CI, 0.49-0.99; P 
.049). No other covariates assessed (Table I) were associ-
ated with restenosis-free survival. Predicted restenosis-free
survival stratified by statin medication use is displayed
graphically in Fig 3.
Clinical manifestations and management of restenosis.
Clinical manifestations and management of restenosis are
summarized in Table III. At a mean postintervention inter-
val of 5.5 months, 28 recurrent lesions were identified in 27
patients. Bilateral restenosis developed in one patient man-
aged with staged bilateral primary RA-PTAS, whereas the
remaining restenoses were unilateral. In 17 of 27 patients
(63%) with restenosis, there were no associated clinical
manifestations such as worsening of hypertension, need for
resumption of previously discontinued antihypertensive
agents, or decline in eGFR after an initial improvement. In
the setting of improvement after RA-PTAS in hypertension
control or renal function, or both, these patients were
managed with continuedmedical therapy andDUS surveil-
lance without repeat angiography. The remaining 10 pa-
tients (37%) with restenosis identified by DUS imaging had
associated hypertension or a decline in eGFR, or both,
prompting repeat intervention. Angiography findings in
these patients confirmed the presence of 60% diameter-
reducing in-stent restenosis in all arteries.
Among individuals who underwent repeat intervention
for restenosis, procedural management initially consisted of
surgical revascularization in one patient and repeat angio-
plasty in nine; four of the nine repeat angioplasties were
performed using cutting balloons. A second restenosis de-
veloped in one patient managed with repeat angioplasty
and was later treated with aortic endarterectomy plus renal
artery bypass. One patient with restenosis was hospitalized
for an acute hypertensive emergency associated with
pulmonary edema and improved clinically with aggressive
medical management. A DUS examination after discharge
from the hospital revealed interval progression of the reste-
nosis to occlusion.
DISCUSSION
This analysis represents an attempt to characterize the
incidence of restenosis after RA-PTAS documented by
DUS follow-up and to characterize associated risk factors.
In a kidney-based analysis of primary RA-PTAS for athero-
sclerotic disease, estimated risk of restenosis was 50% at 12
months and 60% at 18 months. Clinical manifestations,
including worsening of hypertension or decline in eGFR, or
both, were observed frequently in patients with restenosis,
and these patients were most often managed with repeat
erven
JOURNAL OF VASCULAR SURGERY
October 2009816 Corriere et alendovascular treatment. In multivariable proportional haz-
ards analysis, use of statin medications and preintervention
DBP were both associated with decreased risk of restenosis.
DUS imaging has demonstrated validity for identifica-
tion of restenosis after RA-PTAS at a number of cen-
ters.18-21 Among patients studied with renal DUS imaging
before digital subtraction angiography, Bakker et al18 ob-
served a 100% sensitivity and 74% specificity for PSV180
cm/s in determining the presence of restenosis after RA-
PTAS. Using this criterion, the incidence of restenosis
reported in this study is comparable with the incidence
reported by others using DUS imaging for surveillance of
stented renal arteries,6-8 although our validation analysis
(Fig 1, online only) shows PSV 180 cm/s may underes-
timate the true incidence of anatomic restenosis.
In the current study, restenosis was diagnosed at a
relatively early interval after primary RA-PTAS of 5.5
months and was associated with hypertension or decline in
eGFR, or both, in 37% of patients. The poor primary
patency of RA-PTAS for atherosclerotic RAS and the fre-
quent need for repeat intervention underscore the current
controversy regarding benefits of percutaneous treatment
Fig 2. Estimated restenosis-free survival. The estimation
of the survival estimate is 0.1 for the displayed postintof RAS, particularly when considering the modest hyper-tension and renal function benefits observed with this
method.14
Previously described associations with restenosis or the
need for repeat intervention after RA-PTAS include body
weight and body mass index,11 renal artery diameter,5 stent
diameter,9,10 and smoking.12 We were unable to specifi-
cally evaluate body mass index as a predictor of restenosis
due to incomplete patient height data, but did not observe
a significant relationship between weight or any of these
other factors and restenosis in the present study. Post hoc
power analysis confirmed 80% power to detect hazard
ratios 3 for these variables, but power to detect smaller
effect sizes was limited and may have resulted in a type II
statistical error.
Statin use was associated with a significant reduction in
restenosis risk, however, and patients not treated with statin
medications had a nearly threefold increase in estimated risk
for restenosis over time. Although an association between
statin use and restenosis after RA-PTAS has not been de-
scribed previously, to our knowledge, reduction in coronary
artery restenosis associated with statin use has been ob-
served,22 and similar effects on postinjury renal artery remod-
hod accounts for the correlated data. The standard error
tion interval.meteling would therefore seem plausible. Potential mechanisms
estim
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restenosis include effects on serum cholesterol or the com-
position and morphology of atheromatous plaques, or
both. Unfortunately, lipid data within this retrospectively
collected data set was incomplete, precluding meaningful
interpretation of cholesterol values in relationship to statin
Fig 3. Time to restenosis stratified by statin medicatio
becomes broken when the standard error of the survival
Table III. Clinical manifestations and procedural
management of renal artery stenosis after renal artery
percutaneous angioplasty and stenting
No. (%)
Clinical manifestations
Absent 17 (63)
Present 10 (37)
Hypertensiona 6 (60)
Renal dysfunctiona 5 (50)
Hypertensive emergencya 3 (30)
Management
Medical (without procedural intervention) 17
Repeat intervention 10
Repeat angioplasty 8
Surgical revascularization 1
Repeat angioplasty followed by surgical
revascularization 1
aPercentage calculated based on 10 patients with clinical manifestations.use or restenosis.Beneficial pleiotropic effects of statins include favorable
influences on atherosclerotic plaque stability, inflamma-
tion, endothelial function, matrix metalloproteinase activ-
ity, and nitric oxide bioavailability.23,24 Decreased inci-
dence of anatomic progression of atherosclerotic RAS was
observed with statin use by Cheung et al.25 Presumably,
this beneficial effect on natural disease history might also
translate into protection against secondary progression of
atherosclerosis after RA-PTAS.
The relatively rapid development of restenosis we ob-
served after intervention, however, seems more consistent
with neointimal hyperplasia rather than secondary progres-
sion of atherosclerotic disease as the responsible pathophys-
iologic mechanism. Inhibition of vascular smooth muscle
cell migration and proliferation, along with induction of
neointimal smooth muscle cell apoptosis, are previously
described in vitro statin effects26,27 that make protection
against neointimal hyperplasia after RA-PTAS a plausible
hypothesis. Statin-induced plaque stabilization resulting
from increased collagen and reduced lipid content has also
been characterized28 and may contribute to a more favor-
able interface between the stent and the stenotic lesion,
theoretically reducing odds of plaque rupture through
stent interstices at the time of deployment.
We also observed an association between increasing
. Estimation method accounts for correlated data. Line
ate is  0.1.n usepreintervention DBP and freedom from restenosis. Unlike
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ship was unanticipated. Activation of the renin-angiotensin
system is a known stimulus for neointimal hyperplasia.29 Hy-
pothetically, more frequent use of angiotensin-converting en-
zyme (ACE) inhibitors or angiotensin receptor blockers, or
both, among patients with higher baseline DBP might have
resulted in a confounding protective effect against restenosis.
However, no significant differences in baseline blood pres-
sure, number of antihypertensive agents, ACE inhibitors,
or angiotensin receptor blockers were noted between pa-
tients according to restenosis status (Table II), raising the
possibility that this observation may represent a type I
statistical error. In the absence of supporting data from
other studies, we can only speculate about the unexpected
relationship observed between baseline DBP and freedom
from restenosis.
This study provides novel information about factors
associated with restenosis after RA-PTAS; however, several
additional limitations exist that deserve comment. Al-
though restenosis was verified with angiography among all
patients undergoing repeat intervention, most patients
with restenosis did not have associated clinical sequelae and
therefore did not undergo additional confirmatory imag-
ing. Increased rates of positive angiography results have
been observed when patients are studied in the setting of
clinical suspicion,5 and the incidence of restenosis therefore
may have been overestimated due to false-positive DUS
results. Such a possibility is supported by the findings of
Bakker et al,18 who determined renal artery DUS imaging
to be 100% sensitive but only 74% specific for restenosis
after RA-PTAS.
Analysis of clinical disease recurrence (ie, anatomic
restenosis associated with worsening of hypertension or
renal dysfunction), as an alternative outcome therefore might
have increased the specificity of our findings and permitted
angiographic confirmation of DUS results among all patients
experiencing the event. We instead defined restenosis with
DUS imaging given the reliability of this imaging method
at our center and its widespread use as the primary postint-
ervention surveillance method in current clinical practice.
Nonrandom allocation of patients to statin therapy in
this retrospective study also might have resulted in bias if
statin nonuse was a global indicator of suboptimal medical
management, although the stratified comparisons in Table
II seem to argue against this possibility. Finally, symptoms
of restenosis that occurred subsequent to development of a
detectable anatomic lesion might have been missed due to
the relatively short follow-up in this study, which also
precluded analysis of late restenosis.
CONCLUSION
Restenosis after primary RA-PTAS for atherosclerotic
RAS occurs frequently and is often accompanied by physi-
ologic manifestations. Considered in combination with the
beneficial extrarenal cardiovascular effects of statins, the
decreased risk of restenosis associated with use of these
medications supports their routine use in patients undergo-
ing RA-PTAS.AUTHOR CONTRIBUTIONS
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